Evidence map›Paper›PMID 27645240›Full record

ArticleAntimicrobial agents and chemotherapy2016

In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.

Tarani Kanta Barman, Manoj Kumar, Tarun Mathur, Tridib Chaira, G Ramkumar, Vandana Kalia, Madhvi Rao, Manisha Pandya, Ajay Singh Yadav, Biswajit Das and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. PeerJ · 2023
    Article
  3. Article
  4. Review
  5. Review
  6. Azithromycin Exhibits Activity AgainstFrontiers in microbiology · 2021
    Article
  7. Article
  8. Article
  9. Antimicrobial agents and chemotherapy · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Tarani Kanta BarmanDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Manoj KumarDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Tarun MathurDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Tridib ChairaDepartment of Pharmacokinetics & Metabolism, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
G RamkumarDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Vandana KaliaDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Madhvi RaoDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Manisha PandyaDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Ajay Singh YadavDepartment of Medicinal Chemistry, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Biswajit DasDepartment of Medicinal Chemistry, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Dilip J UpadhyayDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
HamidullahCentral Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India.
Rituraj KonwarCentral Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India.
V Samuel RajDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India samuelrajv@yahoo.com harpal2000@yahoo.com.
Harpal SinghCentre for Biomedical Engineering, Indian Institute of Technology, New Delhi, India samuelrajv@yahoo.com harpal2000@yahoo.com.
Daiichi Sankyo (India) · INCentral Drug Research Institute · INIndian Institute of Technology Delhi · INGovernment of India · INSRM University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RBx 11760, a bi-aryl oxazolidinone, was investigated for antibacterial activity against Gram-positive bacteria. The MIC

Indexed as

AnimalsAnti-Bacterial AgentsBiofilmsDisease Models, AnimalDrug Evaluation, PreclinicalDrug Resistance, BacterialGram-Positive BacteriaGram-Positive Bacterial InfectionsLinezolidMaleMiceMicrobial Sensitivity TestsNeutropeniaOrganophosphatesOxazolesOxazolidinonesAnti-Bacterial AgentsLinezolidOrganophosphatesOxazolesOxazolidinonesRBx 11760tedizolid phosphate

Identifiers

PMID27645240
PMCPMC5118992
OpenAlexW2523355558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.